2023-06-26T13:25:04-05:00 2022-12-31 800682248 CHARLES M MOCHE CPA 2050 CENTER AVENUE SUITE 435 FORT LEE NJ 07024 990 2022-01-01 562427805 AIM AT MELANOMA AIMA 9167060599 3040 CUTTING BLVD RICHMOND CA 94804 SAMANTHA GUILD PRESIDENT 9167060599 2023-06-26 1 SAMANTHA GUILD 999009999 1 CHARLES M MOCHE P00641894 2014651800 2023-06-26 X 2 AAL1 IAL1 2022 2023-04-26 12:10:37Z SAMANTHA GUILD 3040 CUTTING BLVD RICHMOND CA 94804 3699681 0 X WWW.AIMATMELANOMA.ORG X 2004 CA TO SUPPORT MELANOMA RESEARCH; TO PROMOTE PREVENTION AND EDUCATION AMONG THE GENERAL PUBLIC AND MEDICAL PROFESSIONALS; AND TO PROVIDE COMPREHENSIVE AND EASILY ACCESSIBLE MELANOMA RESOURCES FOR PATIENTS, SURVIVORS, AND CAREGIVERS. 5 4 9 0 0 0 2730026 2571483 59471 9500 13358 5328 98402 0 2901257 2586311 228200 248000 0 0 807320 815922 0 0 67588 806678 1130816 1842198 2194738 1059059 391573 4688149 5081407 6335 8020 4681814 5073387 X AIM AT MELANOMA (AIM) IS GLOBALLY ENGAGED AND LOCALLY INVESTED IN ADVANCING THE BATTLE AGAINST MELANOMA THROUGH INNOVATIVE RESEARCH, LEGISLATIVE REFORM, EDUCATION, AND PATIENT AND CAREGIVER SUPPORT. FOUNDED IN 2004, AIM AT MELANOMA IS THE LARGEST INTERNATIONAL MELANOMA FOUNDATION SEEKING THE CURE FOR MELANOMA. AIM BELIEVES THAT THE CURE FOR MELANOMA WILL BE FOUND MORE QUICKLY BY BRINGING TOGETHER LEADING GLOBAL RESEARCHERS AND FUNDING THEIR COLLABORATIVE RESEARCH. OUR THREE PARADIGM-SHIFTING GLOBAL RESEARCH INITIATIVES, INCLUDING THE MELANOMA TISSUE BANK CONSORTIUM, ARE POISED TO RESHAPE THE FUTURE OF MELANOMA. AIM IS THE RESPECTED VOICE OF MELANOMA ACROSS THE NATION. WHEN DRUGS ARE APPROVED, LEGISLATION IS DRAFTED, AND RESEARCH IS ASSESSED, AIM IS AT THE TABLE, SPEAKING LOUDLY AND CLEARLY ON BEHALF OF PATIENTS AND THEIR FAMILIES. AIM IS THE TRUSTED ADVISOR FOR PHARMACEUTICAL COMPANIES, MEDICAL BOARDS, AND GOVERNMENT AGENCIES ON CRITICAL TOPICS THAT AFFECT MELANOMA PATIENTS. 0 0 1980799 248000 WEBSITEAIM AT MELANOMA ("AIM") IS AN INTERNATIONAL ORGANIZATION ENGAGED IN A WIDE VARIETY OF PATIENT ADVOCACY INITIATIVES. AMONG THESE IS THE MAINTENANCE OF THE MOST COMPREHENSIVE U.S. WEBSITE ON MELANOMA (WWW.AIMATMELANOMA.ORG). IN 2022, AIM CONTINUED TO ADD MORE CONTENT SO IT WOULD BETTER BE ABLE TO MEET THE NEEDS OF THE MELANOMA COMMUNITY. THIS INCLUDED MAKING IT EASIER FOR USERS TO LOCATE PERTINENT INFORMATION TO ASSIST THEM IN BETTER UNDERSTANDING THEIR MELANOMA DIAGNOSIS, RISK OF RECURRENCE, DETERMINING THEIR TREATMENT OPTIONS, MANAGE THE SIDE EFFECTS OF TREATMENT, UNDERSTANDING FOLLOW-UP CARE AND ADDRESS THE PSYCHOSOCIAL ASPECTS OF THE DISEASE. THE ORGANIZATION CONTINUED TO USE VARIOUS TOOLS SUCH AS SEARCH ENGINE OPTIMIZATION AND DISTRIBUTING BROCHURES TO HEALTHCARE PROVIDERS THROUGHOUT THE U.S. TO EDUCATE MELANOMA PATIENTS ABOUT THE WEBSITE'S RESOURCES. THE WEBSITE WAS ALSO UPDATED REGULARLY FOR MEDICAL ACCURACY IN ORDER TO REFLECT THE CURRENT STANDARD OF CARE IN MELANOMA AND WITH CONTENT RELATED TO ISSUES FACING THE MELANOMA COMMUNITY. THE U.S. WEBSITE ALONE, HAD MORE THAN 65,000 UNIQUE VISITORS EACH MONTH.PATIENT ADVOCACYAIM CONTINUED TO PROVIDE A FREE PHYSICIAN ASSISTANT ON CALL SERVICE. THROUGHOUT THE YEAR, MELANOMA PATIENTS, CAREGIVERS, AND FAMILIES REACHED OUT TO AIM'S ONCOLOGY PHYSICIAN ASSISTANT TO ASK QUESTIONS ABOUT, AMONG OTHER THINGS, THEIR/OR THEIR LOVED ONE'S MELANOMA DIAGNOSIS, TREATMENT OPTIONS, CLINICAL TRIALS, AND FOLLOW-UP CARE AS WELL AS QUESTIONS REGARDING PREVENTION AND EARLY DETECTION OF THE DISEASE. AIM ALSO COORDINATED NUMEROUS PATIENT ADVOCACY EVENTS, WHICH INCLUDED 10 PATIENT AND CAREGIVER SYMPOSIA LED BY NATIONALLY RECOGNIZED MELANOMA ONCOLOGISTS AT MAJOR CANCER CENTERS SUCH AS MD ANDERSON CANCER CENTER, UNIVERSITY OF MICHIGAN HEALTH SYSTEMS, NYU LANGONE PERMUTTER CANCER CENTER, UNIVERSITY OF COLORADO CANCER CENTER FOR RARE MELANOMAS, AND MOFFITT CANCER CENTER. THE SYMPOSIA BEGAN TO RETURN TO IN-PERSON EVENTS. ATTENDEES ALSO LIVE STREAMED GLOBALLY. AIM ALSO VIDEOTAPED AND EDITED THESE SYMPOSIUMS, WHICH WERE THEN UPLOADED ONTO YOUTUBE AND AIM'S WEBSITE SO THAT THEY COULD BE VIEWED BY INDIVIDUALS IN THE U.S. AND WORLDWIDE. AIM CONTINUED TO PROVIDE SUPPORT FOR PATIENTS, FAMILIES, AND SURVIVORS THROUGH A PROGRAM CALLED PEER CONNECT. PEER CONNECT IS A PEER-TO-PEER SUPPORT PROGRAM, AIM AT MELANOMA'S ANSWER TO THE ONGOING NEED FOR SUPPORT IN THE MELANOMA COMMUNITY. MELANOMA PATIENTS, FAMILY MEMBERS, AND CAREGIVERS WHO JOIN THE PROGRAM ARE MATCHED WITH A PEER, AND FROM THERE THE PAIR COMMUNICATE IN A WAY THAT IS COMFORTABLE FOR BOTH. MEMBERS OF PEER CONNECT PROVIDE EACH OTHER WITH KNOWLEDGE, EXPERIENCE, EMOTIONAL SUPPORT, AND MORE.AIM MAINTAINED A FACEBOOK PAGE, WHICH NOW HAS OVER 25,500 FOLLOWERS, A TWITTER ACCOUNT OF OVER 7,800 FOLLOWERS AND AN INSTAGRAM ACCOUNT OF OVER 2,800 FOLLOWERS IN ORDER TO PROVIDE OTHER SOURCES OF INFORMATION FOR THE MELANOMA COMMUNITY.AIM CONTINUED TO REPRESENT PATIENTS ON THE TWO LARGEST U.S. COOPERATIVE ONCOLOGY GROUPS, SWOG AND ECOG, THE NCCN, AND THE ASCO GUIDELINES COMMITTEE. AIM ALSO PRESENTED ON THE MELANOMA PATIENT PERSPECTIVE AT NUMEROUS MEETINGS BOTH IN THE U.S. AND THROUGHOUT THE WORLD, WHICH RETURNED TO IN-PERSON FORMAT IN 2022. TO HELP PATIENTS UNDERSTAND THEIR DISEASE, AIM CONTINUED TO OFFER FROM THE CLINIC TO THE LIVING ROOM, A WEBINAR SERIES THAT IS LIVE STREAMED THROUGH FACEBOOK TO PROVIDE AN IN-DEPTH DISCUSSION ON A SPECIFIC TOPIC WITH A MELANOMA SPECIALIST, SUCH AS A PHYSICIAN, RESEARCHER, OR OTHER MEDICAL EXPERT. AIM ALSO CONTINUED TO OFFER BEYOND THE CLINIC: LIVING WELL WITH MELANOMA, A PODCAST SERIES TO ADDRESS THE PSYCHOSOCIAL ASPECTS OF A MELANOMA DIAGNOSIS DURING AND BEYOND TREATMENT. AIM ALSO CONTINUED TO OFFER MELANOMA360 BLOG, WHICH FEATURES SURVIVOR STORIES, RESEARCH BREAKTHROUGHS, CURRENT NEWS, HEALTH LIVING INFORMATION ETC.GLOBAL ADVOCACYAIM'S PATIENT ADVOCACY IS A GLOBAL EFFORT. IN 2022, AIM CONTINUED TO SUPPORT AND MENTOR PATIENT ADVOCACY GROUPS IN THE UNITED KINGDOM, PORTUGAL, GERMANY, FRANCE, ITALY, SPAIN, ISRAEL, LATIN AMERICA, BRAZIL, CANADA, AUSTRALIA, AND EASTERN EUROPE. AIM MADE IT POSSIBLE FOR THE PATIENT ADVOCATES TO ATTEND INTERNATIONAL MELANOMA MEETINGS, EITHER IN PERSON OR VIRTUALLY, WHERE THEY LEARNED ABOUT THE MOST UP TO DATA ON MELANOMA, AND WHERE THEY PRESENTED THE PATIENT PERSPECTIVE TO RELEVANT GROUPS. AIM CONTINUED TO ASSIST IN THE DEVELOPMENT OF SOME OF THEIR RESPECTIVE WEBSITES PROVIDING NOT ONLY TECHNICAL SUPPORT BUT ALSO MATERIAL FOR THE SITES, WHICH INCLUDED A SERIES OF VIDEOS DISCUSSING IMMUNOTHERAPY COMBINATION THERAPY; CURRENT AND EMERGING APPROACHES AND PROVIDER MATERIALS TO HELP RECOGNIZE AND MANGE THE SIDE EFFECTS OF TARGETED THERAPIES. AIM HELD ITS YEARLY IN PERSON MEETING FOR GLOBAL PATIENT ADVOCATES IN ORDER TO HELP THEM LEARN MORE ABOUT MELANOMA ADVANCEMENTS AS WELL AS HOW TO USE SOCIAL MEDIA TO EDUCATE PATIENTS AND CAREGIVERS. AIM ALSO HELD ZOOM TEAM MEETINGS FOR GLOBAL ADVOCATES TO ALLOW FOR THE ABILITY TO COLLABORATE ON YEAR-LONG PROJECTS, TO PROVIDE EACH OTHER FEEDBACK ON INDIVIDUAL REGIONAL PROJECTS, TO SHARE BEST PRACTICES AND LEARNINGS IN REAL TIME WITH EACH OTHER, AND TO LEARN ABOUT RESULTS OF CLINICAL TRIALS.IMWGIN APRIL 2006, AIM FORMED THE INTERNATIONAL MELANOMA WORKING GROUP (IMWG). THE IMWG IS BASED ON THE PREMISE THAT MELANOMA REQUIRES A FOCUSED, MULTI-DISCIPLINARY EFFORT AMONG THE WORLD'S LEADING MELANOMA INVESTIGATORS IN ORDER TO PROVIDE FOR A BETTER UNDERSTANDING OF THE BIOLOGY OF MELANOMA, TO ACCELERATE THE QUEST FOR MORE EFFECTIVE THERAPIES, AND EVENTUALLY TO DEVELOP A CURE FOR THE DISEASE. THE IMWG PROVIDES A THINK TANK ATMOSPHERE FOR THE WORLD'S LEADING MELANOMA EXPERTS TO GATHER AWAY FROM LARGE MEETINGS. SINCE ITS INCEPTION, IMWG HAS UNDERTAKEN SEVERAL KEY PROJECTS AS A RESULT OF COLLABORATION AMONG ITS MEMBERS AND CONTINUES TO WORK ON ADDITIONAL EFFORTS THAT WILL LEAD TO THE DEVELOPMENT OF MORE EFFECTIVE TREATMENT OPTIONS FOR MELANOMA PATIENTS. IMWG MEMBERS, WHICH CONSIST OF OVER FORTY MELANOMA EXPERTS FROM THROUGHOUT THE WORLD, MET VIRTUALLY IN THE SPRING 2022 AND RETURNED TO AN IN-PERSON FORMAT IN THE FALL OF 2022. AMONG ITS ACCOMPLISHMENTS IN 2022, THE IWMG CONTINUED TO WORK ON ITS INTERNATIONAL CLINICAL TRIAL NETWORK. AIM HAS OPENED AN INTERNATIONAL MELANOMA TISSUE BANK OF ANNOTATED FRESH FROZEN PRIMARY MELANOMA TISSUE AT OREGON HEALTH & SCIENCE UNIVERSITY'S KNIGHT CANCER INSTITUTE, CALIFORNIA PACIFIC MEDICAL CENTER, NORTHWESTERN UNIVERSITY'S ROBERT H. LURIE COMPREHENSIVE CANCER CENTER, UNIVERSITY OF PITTSBURGH CANCER INSTITUTE, THE PETER MACCALLUM CANCER CENTER AND ALFRED HOSPITAL IN MELBOURNE. THE TISSUE BANK IS THE FUNDAMENTAL RESEARCH TOOL THAT DOES NOT EXIST YET FOR PUBLIC OR PRIVATE RESEARCH. MAJOR ADVANCES, PARTICULARLY WITHIN BREAST AND PROSTATE CANCER, RESULTED FROM SIMILAR BANKS. CONSEQUENTLY, MELANOMA RESEARCH LAGS SIGNIFICANTLY BEHIND THE PROGRESS THAT HAS BEEN MADE IN OTHER CANCER RESEARCH. IN 2022, THE BANK COLLECTED TISSUE FROM ALL 4 U.S. SITES AND CONTINUED ITS EFFORT TO START COLLECTING TISSUE AT ITS AUSTRALIAN SITES.WIMIN AUGUST 2017, AIM FORMED WOMEN IN MELANOMA (WIM). WITH A GROWING NUMBER OF YOUNG WOMEN ONCOLOGISTS WITH AN INTEREST IN MELANOMA, AND AIM'S PROVEN TRACK RECORD FOR BRINGING TOGETHER MELANOMA EXPERTS, AIM FORMED WIM FOR THE PURPOSE OF; SUPPORTING THE IMPROVEMENT OF MELANOMA PATIENT OUTCOMES THROUGH A FOCUS ON STRENGTHENING THE PHYSICIAN-PATIENT RELATIONSHIP, PROVIDING INSIGHTS INTO BEST PRACTICES IN COMMUNICATING WITH PATIENTS WITH MELANOMA TO IMPROVE OUTCOME, SUPPORTING THE ACADEMIC CAREERS OF YOUNG WOMEN WITH A RESEARCH INTEREST IN MELANOMA, AND FOSTERING MENTORING RELATIONSHIPS AMONG WOMEN ONCOLOGISTS WORKING IN THE FIELD OF MELANOMA. IN 2022, AIM HELD ITS SIXTH ANNUAL MEETING IN LEESBURG, VA WHICH WAS ATTENDED BY UP-AND-COMING WOMEN ONCOLOGISTS, WITH A FOCUS ON MELANOMA. SINCE ITS INCEPTION, WIM MEMBERS HAVE SINCE UNDERTAKEN KEY RESEARCH PROJECTS AS A RESULT OF COLLABORATION AMONG ITS MEMBERS AT WIM MEETINGS.NURSE/PHYSICIAN EDUCATION INITIATIVEIN OCTOBER 2016 AIM CREATED THE MELANOMA NURSE INITIATIVE (MNI). THE RECENT EXPANSION OF MELANOMA THERAPY HAS INCREASED THE COMPLEXITY OF DISEASE MANAGEMENT. PATIENTS MAY DISCONTINUE THERAPY IF NOT ADEQUATELY ENGAGED IN THEIR OWN CARE OR SUPPORTED WHEN THEY EXPERIENCE SIDE EFFECTS. AS WELL, MORE PATIENTS ARE BEING TREATED IN THE COMMUNITY SETTING, WHERE EXPERTISE IS FREQUENTLY LACKING TO ADDRESS THESE CHALLENGES. THE MNI CONSISTS OF:1. MELANOMA NURSE RESOURCE CENTER PORTAL (SEE GRAPHIC, THEMELANOMANURSE.ORG)THIS PORTAL PROVIDES A 1-STOP SHOP FOR ALL THE EDUCATIONAL MATERIALS DEVELOPEDCONTENT INCLUDES CONSENSUS STATEMENTS, SIDE-EFFECT SEARCH FUNCTIONS, CNE ACTIVITIES, A SUPPORTIVE CARE Q/A PORTAL, AND A PATIENT RESOURCE CENTER.2. MELANOMA NURSE MANAGEMENT TOOLKITHELPFUL RESOURCES SUCH AS ALGORITHMS, CHECKLISTS, PRINTABLE SHEETS, AND CONTINUED FROM SCHEDULE OSEARCHABLE CONTENT ON SUPPORTIVE CARE ASPECTS OF MELANOMA THERAPY (SIDE EFFECT MANAGEMENT AS WELL AS ADHERENCE ISSUES), KEY RESOURCES ON TARGETED THERAPY, IMMUNOTHERAPY, AND INTRALESIONAL IMMUNOTHERAPY ONLINE RESOURCES AS WELL AS PRINT PIECES FOR DISTRIBUTION AT REGIONAL CANCER MEETING.3. CJON (ONS) SUPPLEMENT ON OPTIMIZING OUTCOMES FOR MELANOMA THERAPIES 7-ARTICLE SUPPLEMENT IN CJON TO INCLUDE AN INTRODUCTION BY 2 MELANOMA PHYSICIANS, AN OVERVIEW DOCUMENT FROM OUR CHAIR, AND 5 ARTICLES ON SUPPORT STRATEGIES FOR TARGETED THERAPY, IMMUNOTHERAPY, AND INTRALESIONAL IMMUNOTHERAPY ARTICLES ARE MADE AVAILABLE THROUGH OPEN ACCESS LOCATED ON OUR PORTAL.4. JADPRO SUPPLEMENT ON THE MANAGEMENT OF IMMUNE RELATED ADVERSE EVENTS THIS 4-ARTICLE SUPPLEMENT IN JADPRO COVERS IMMUNO-ONCOLOGY THERAPY ESSENTIALS: PROACTIVE MANAGEMENT OF IMMUNE-RELATED ADVERSE EVENTS. BOTH THE CJON AND JADPRO SUPPLEMENTS ARE AVAILABLE AS WELL ON THE MNI WEBSITE.5. JCO ONCOLOGY PRACTICE ON INTERDISCIPLINARY CARE FOR MANAGEMENT OF COMPLEX IRAES. THE ARTICLES IN THE SUPPLEMENT COVERS IMMUNO-ONCOLOGY APPLICATIONS IN CLINICAL SCENARIOSINTRODUCTION, TOXICITY MANAGEMENT OF FRONT-LINE PEMBROLIZUMAB COMBINED WITH AXITINIB IN CLEAR CELL METASTATIC RENAL CELL CARCINOMA: A CASE STUDY APPROACH, MANAGEMENT OF PNEUMONITIS AND NEUROPATHY IN PATIENTS RECEIVING PD-1BASED THERAPY FOR NONSMALL-CELL LUNG CANCER, THE MANAGEMENT OF IMMUNE-RELATED DERMATITIS AND MUCOSITIS ASSOCIATED WITH PEMBROLIZUMAB IN METASTATIC HUMAN PAPILLOMAVIRUSASSOCIATED SQUAMOUS CELL CARCINOMA OF THE OROPHARYNX, AND ATYPICAL PRESENTATIONS AND MANAGEMENT OF ENDOCRINE AND HEPATIC IMMUNE-RELATED ADVERSE EVENTS FROM ADJUVANT IMMUNE CHECKPOINT INHIBITOR THERAPY IN STAGE III RESECTED MELANOMA. THE JCO SUPPLEMENT ARE AVAILABLE AS WELL ON THE MNI WEBSITE.6. AIM CONTINUED TO PROVIDE AN INTERACTIVE, WEB BASED EDUCATION ON BRAF/MEK INHIBITOR THERAPY FOR MELANOMA TO IMPROVE THE OUTCOMES THROUGH INDISCIPLINARY CARE. THE EDUCATION IS AVAILABLE AS WELL ON THE MNI WEBSITE.7. DEVELOPMENT OF PATIENT RESOURCE MATERIALS CUSTOMIZED PATIENT RESOURCE/EDUCATION MATERIALS (PRINTABLE PDFS) HAVE BEEN DEVELOPED THAT CAN BE DOWNLOADABLE FROM THE WEBSITE AND DISTRIBUTED BY NURSES/PHYSICIAN ASSISTANTS AND OTHER HCPS. TOPICS INCLUDE THE GOALS OF THERAPY, THE SIDE EFFECTS OF THERAPIES, IMPORTANT POINTS/STRATEGIES AROUND ADHERENCE, AS WELL AS OTHER SUPPORTIVE RESOURCES, SUCH AS CALL-IN NUMBERS FOR FINANCIAL OR OTHER ASSISTANCE, ETC. SPECIFIC CONTENT ON TARGETED THERAPIES, IMMUNOTHERAPIES, COMBINATIONS, INTRALESIONAL IMMUNOTHERAPIES, AND THE ADJUVANT SETTING ARE INCLUDED.8. DEVELOPMENT OF PATIENT AND HCP VIDEOS HAVE BEEN DEVELOPED TO ADDRESS THE ISSUES OF PREVENTION AND EARLY DETECTION, SURGERY, PATHOLOGY, TREATMENT, SIDE EFFECTS AND MANAGMENET FOR BOTH TARGETED AND IMMUNOTHERAPIES, CLINICAL TRIALS, AND LIVING WITH MELANOMA. THE HCP VIDEOS WERE DEVELOPED TO ASSIST HCPS TO CARE FOR PATIENTS DURING COVID. THE VIDEOS ARE AVAILABLE ON AIM AT MELANOMA SITE'S YOUTUBE CHANNEL.9. AIM PROVIDED WEB BASED EDUCATION ON STRATEGIES TO SUPPORT SHARED DECISION MAKING IN THE STAGE IV SETTING. THE EDUCATION IS AVAILABLE AS WELL ON THE MNI WEBSITE. 1980799 1 1 0 0 0 0 0 0 0 0 1 0 0 0 1 0 1 0 0 0 0 0 0 0 1 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 8 0 1 9 1 0 0 0 0 0 0 0 0 0 0 X 5 4 0 0 0 0 0 0 0 1 1 0 0 1 1 1 0 1 1 0 0 0 CA X THE ORGANIZATION 9167060599 3040 CUTTING BLVD RICHMOND CA 94804 JOHN KIRKWOOD DIRECTOR 3.00 X 0 0 0 MOHAMMED KASHANI-SABET DIRECTOR 3.00 X 0 0 0 RENU GUPTA DIRECTOR 1.00 X 0 0 0 HOWARD MAIBACH DIRECTOR 1.00 X 0 0 0 SAMANTHA GUILD PRESIDENT AND DIRECTOR 60.00 X X 187000 0 22963 ALICIA ROWELL VICE PRESIDENT 40.00 X 160008 0 0 347008 0 22963 2 0 1 0 0 342368 2229115 973 2571483 CONSULTING 541900 5000 5000 HONORARIUM 541900 4500 4500 9500 20339 20339 1012603 1027614 -15011 -15011 -15011 85756 342368 85756 0 2586311 9500 0 5328 248000 248000 347008 321657 9350 16001 339108 288242 16955 33911 78652 69150 3933 5569 51154 45472 1961 3721 26645 26645 4543 4543 56156 13000 43156 37905 37905 6446 6446 17930 17930 PATIENT EDUCATION AND S 355571 355571 PHYSICIAN/NURSE EDUCATI 297262 297262 RESEARCH MEETINGS 127088 127088 GLOBAL ADVOCACY 52986 52986 148284 139898 8386 2194738 1980799 146351 67588 851490 784907 3815883 4277158 1517 82891 65066 20776 17825 4688149 5081407 6335 8020 6335 8020 X 0 0 0 0 4681814 5073387 4681814 5073387 4688149 5081407 391573 0 X X 0 0 0 X 2540964 2552720 2133571 2730026 2571483 12528764 2540964 2552720 2133571 2730026 2571483 12528764 6619610 5909154 3344 18928 33124 13358 5328 74082 168365 157873 9500 335738 12938584 0.45670 0.43960 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 82891 65066 17825 17825 PENSION PAYABLE 2962 INSURANCE PAYABLE 5058 8020 2571483 0 2571483 14828 14828 2586311 2194738 0 2194738 0 2194738 PART XI, LINE 4B - OTHER ADJUSTMENTS: INVESTMENT INCOME 5,328. CONSULTING AND HONORARIUM 9,500. AIM FOR THE "CURE MELANOMA WALKS" 342368 342368 342368 342368 342368 1 OHSU KNIGHT CANCER INSTITUTE 1121 SW SALMON STREET PORTLAND OR 97205 237083114 10000 0 CANCER AND MELANOMA RESEARCH UPMC UNIV OF PITTSBURGH CANCER INSTITUTE 5150 CENTRE AVENUE PITTSBURGH PA 15232 250965591 38000 0 CANCER AND MELANOMA RESEARCH MTBC MELANOMA TISSUE BANK CONSORTIUM 1779 MARKHAM WAY SACRAMENTO CA 95818 462454076 200000 0 TISSUE BANK X X 0 0 0 0 0 0 0 0 0 SAMANTHA GUILD PRESIDENT AND DIRECTOR 162000 0 25000 0 0 0 0 0 22963 0 209963 0 0 0 ALICIA ROWELL VICE PRESIDENT 160008 0 0 0 0 0 0 0 0 0 160008 0 0 0 FORM 990, PART VI, SECTION B, LINE 11B FORM 990 IS SUBMITTED BY THE ACCOUNTANT TO THE GOVERNING BODY FOR REVIEW AND DISCUSSION. THE PRESIDENT APPROVES THE FILING OF FORM 990 BASED ON COMPLIANCE AND ACCURACY. THE ACCOUNTANT IS THEN GIVEN AUTHORIZATION TO FILE. FORM 990, PART VI, SECTION C, LINE 19 ALL GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY AND APPLICABLE FINANCIAL STATEMENTS ARE AVAILABLE TO THE PUBLIC UPON REQUEST FORM 990 PART XII LINE 2C A COMMITTEE ASSUMES RESPONSIBILITY FOR THE OVERSIGHT OF THE AUDIT, REVIEW OR COMPILATION OF ITS FINANCIAL STATEMENTS AND SELECTION OF ITS INDEPENDENT AUDITORS. THE ORGANIZATION DID NOT CHANGE ITS OVERSIGHT OR SELECTION PROCESS DURING THE TAX YEAR.